Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

OCTRU/CSM have recruited a new lead statistician to join the team.

Dr Iftekhar Khan has joined the CTU this week as Lead Statistician for our early phase and oncology trial portfolio. He joins us from King’s College, London, and prior to this he has worked in academia and industry over the last 15 years on clinical trials.

 

Dr Khan spoke to us about his interests and previous experience:

''I come with over 15 years experience in academia, industry and MHRA as a statistician. In previous jobs I have been head of Phase I at Eli LIlly, Merck and was responsible for Phase I trials at the UCL CRUK Cancer Trials Centre. I am also a senior statistical assessor within the licensing division of the MHRA. My interests lie in two areas at the extremes of the drug development spectrum: Phase I and Statistical Methods in Health Economics (I also happen to be a qualified health economist). I have written books on Design & Analysis of Clinical Trials for Economic Evaluation (Chapman & Hall; 2015); Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data (Chapman & Hall April 2019); and a forthcoming book on Sample Sizes For Clinical trial Trials Using Bayesian Methods (Chapman & Hall, due late 2019).

 I also like sailing, walking/trekking and playing cricket (when I can!).''

 

We look forward to expanding our portfolio of early phase trials with Dr Khan’s guidance.

Similar stories

New centre aims to help companies conduct more efficient trials

Botnar Main Trials

A new clinical therapeutics centre has been set up by the University of Oxford to help life sciences companies identify interventions that have the greatest potential to deliver patient benefit, and so bring down the cost of early phase clinical trials.

AVID-CC trial opens to recruitment!

OCTRU

The AVID-CC trial has received OCTRU Green Light approval and is now open to recruitment!

WHiTE Four trial results published

Hip Main OCTRU Orthopaedics and trauma Research Trauma

The results of the WHiTE Four clinical trial for the treatment of fragility hip fractures have been published in The Bone and Joint Journal.

Understanding the first wave of COVID-19 and implications for tackling the ongoing pandemic: evidence from 5.5 million people from Catalonia, Spain

Botnar Main Research Statistics and epidemiology

Health outcomes during the first wave of COVID-19 in Catalonia, Spain, have been described in detail in a study published by Nature Communications.

A more tailored approach to treating psoriatic arthritis

Arthritis Botnar Funding Main

Dr Laura Coates has been awarded £1.8M from the National Institute for Health Research (NIHR) to explore the potential for precision medicine in the choice of biologics to reduce inflammation and pain in psoriatic arthritis.

WHiTE Four trial results!

OCTRU

The WHiTE Four trial has now published its results in The Bone & Joint journal.